Last reviewed · How we verify

DTaP-IPV-Hep B-PRP~T combined vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV-Hep B-PRP~T combined vaccine is a Combination vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTaP-IPV-Hep B-PRP~T combined vaccine
SponsorSanofi Pasteur, a Sanofi Company
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

The vaccine contains inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, hepatitis B surface antigen, and conjugated Haemophilus influenzae type b polysaccharide. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, providing protection against these six infectious diseases through the development of immunological memory.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV-Hep B-PRP~T combined vaccine

What is DTaP-IPV-Hep B-PRP~T combined vaccine?

DTaP-IPV-Hep B-PRP~T combined vaccine is a Combination vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

How does DTaP-IPV-Hep B-PRP~T combined vaccine work?

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

What is DTaP-IPV-Hep B-PRP~T combined vaccine used for?

DTaP-IPV-Hep B-PRP~T combined vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

Who makes DTaP-IPV-Hep B-PRP~T combined vaccine?

DTaP-IPV-Hep B-PRP~T combined vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

What drug class is DTaP-IPV-Hep B-PRP~T combined vaccine in?

DTaP-IPV-Hep B-PRP~T combined vaccine belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTaP-IPV-Hep B-PRP~T combined vaccine in?

DTaP-IPV-Hep B-PRP~T combined vaccine is in Phase 3.

What are the side effects of DTaP-IPV-Hep B-PRP~T combined vaccine?

Common side effects of DTaP-IPV-Hep B-PRP~T combined vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related